A preparation of natural killer (NK) cells that are engineered to express a T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME), with potential antineoplastic activity. Upon administration, the PRAME-targeting TCR-engineered NK cells specifically recognize and bind to PRAME expressed on cancer cells, thereby lysing the PRAME-expressing cancer cells. PRAME is overexpressed by a variety of cancer cell types.